PP
OCUL icon

PDT Partners’s Ocular Therapeutix OCUL Stock Holding History

PDT Partners’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-65,350
Closed -$344K – 632
2023
Q1 		$344K Buy
+65,350
New +$310K 0.05% 438
2015
Q3 		– Sell
-39,887
Closed -$839K – 1476
2015
Q2 		$839K Buy
39,887
+28,416
+248% +$704K 0.02% 796
2015
Q1 		$482K Buy
+11,471
New +$377K 0.01% 1027

Other funds holding OCUL

SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

PDT Partners's OCUL Position: Q2 2023 in Review

PDT Partners sold out of Ocular Therapeutix (OCUL) in Q2 2023, closing a stake of 65,350 shares — an estimated $344K sold.

PDT Partners first reported a position in OCUL in Q1 2015 and held it in 3 quarters. The position peaked at $839K in Q2 2015. 135 funds tracked by Wall St. Rank hold OCUL as of Q2 2023.

  • PDT Partners reported no remaining Ocular Therapeutix position as of Q2 2023 after selling out during the quarter.
  • PDT Partners sold 65,350 Ocular Therapeutix shares in Q2 2023, an estimated $344K.
  • PDT Partners first reported a position in Ocular Therapeutix in Q1 2015 and held it in 3 quarters.
  • PDT Partners's Ocular Therapeutix position peaked at $839K in Q2 2015.
  • 135 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2023.

Based on PDT Partners's 13F filing for Q2 2023, filed 14 Aug 2023.